The senior leaders of the Consortium include sixteen individuals: The Director, the Deputy Director, ten Associate Directors, the Consortium Administrator, and three Deputy Associate Directors. The Associate Directors provide oversight and coordination of the Consortium's scientific disciplines of basic sciences, clinical sciences, and public health sciences. They co-direct the oversight and coordination of various Consortium processes, including planning and evaluation, shared resources, membership, and allocation of developmental funds. In addition, they serve as institutional representatives. The three independent institutions in the Consortium have different cultures and locations, so these individuals have a strong communication role to ensure that the members within their institutions are aware of activities and issues of the Consortium. In addition to representing the interests of the Consortium at their institutions, they also represent the interests of their institutions within the Consortium. The Deputy Associate Directors leaders are responsible for scientific planning for the Consortium, formation and management of the Consortium interdisciplinary goals for coordinating internal program review, shared resources review, and review of pilot funding. These functions are accomplished through their leadership of the Consortium Scientific Steering Committee, in which they enlist the help and support of the Consortium program leaders for these activities. The Consortium Administrator is responsible for implementation of the Consortium goals and objectives, and coordination of Consortium and CCSG administrative and management support activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-39S1
Application #
8607290
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-01-01
Project End
2013-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
39
Fiscal Year
2013
Total Cost
$109,383
Indirect Cost
$47,234
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Jeong, Kyoung Sook; Zhou, Jin; Griffin, Stephanie C et al. (2018) MicroRNA Changes in Firefighters. J Occup Environ Med 60:469-474
Appelbaum, Jacob; Wells, David; Hiatt, Joseph B et al. (2018) Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 6:82
Blair, Kris M; Mears, Kevin S; Taylor, Jennifer A et al. (2018) The Helicobacter pylori cell shape promoting protein Csd5 interacts with the cell wall, MurF, and the bacterial cytoskeleton. Mol Microbiol 110:114-127
Talarico, Sarah; Korson, Andrew S; Leverich, Christina K et al. (2018) High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. Helicobacter 23:e12472
Bhatia, Shailender; Miller, Natalie J; Lu, Hailing et al. (2018) Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clin Cancer Res :
Chozinski, Tyler J; Mao, Chenyi; Halpern, Aaron R et al. (2018) Volumetric, Nanoscale Optical Imaging of Mouse and Human Kidney via Expansion Microscopy. Sci Rep 8:10396
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659

Showing the most recent 10 out of 1267 publications